New Product Registration at GP Pharm

In November GP Pharm has obtained in Spain the approval for the Octreotide as generic product in four different presentations. (50mg/mL, 100mg/mL and 500mg/mL in ampoules, and 200mg multidose vials). This product has been filed also in Portugal and other countries in Europe and Australia and at this point GP Pharm is waiting for their approval.

In addition to the Octreotide for injection marketing authorization, GP Pharm has achieved also registrations for Bicalutamide and Tamsolusine.

By the end of this year, GP Pharm wishes to have completed 4 registration dossiers approval and 2 more products are on the line for next approvals (Irinotecan and Oxaliplatin). These products will be part of the GP Pharm’s future commercial sales force Vademecum for Spain and South America and available for licence.